-
- Jonas Kühn
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Etienne Shaffer
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Julien Mena
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Billy Breton
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Jérôme Parent
- Center of Psychiatric Neurosciences (CNP), The University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Prilly, Switzerland.
-
- Benjamin Rappaz
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Marc Chambon
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Yves Emery
- Lyncée Tec SA, PSE-A, Lausanne, Switzerland.
-
- Pierre Magistretti
- Center of Psychiatric Neurosciences (CNP), The University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Prilly, Switzerland.
-
- Christian Depeursinge
- MicroVision and MicroDiagnostics Group (CHD), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
-
- Pierre Marquet
- Center of Psychiatric Neurosciences (CNP), The University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Prilly, Switzerland.
-
- Gerardo Turcatti
- Biomolecular Screening Facility (BSF), Swiss Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
収録刊行物
-
- ASSAY and Drug Development Technologies
-
ASSAY and Drug Development Technologies 11 (2), 101-107, 2013-03
Mary Ann Liebert Inc